Category: news

SAN RAFAEL, Calif., Jan. 15, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it completed the initial offering period for the previously announced tender offer for all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA). As a result, BioMarin will purchase approximately 93.4% of Prosensa’s outstanding shares pursuant to the… Continue reading BioMarin Announces Completion of Tender Offer for Prosensa’s Shares and Commences Subsequent Offering Period

~ Data confirms the potential of ATIR™ in partially matched hematopoietic stem cell transplants ~ Amsterdam, The Netherlands, December 9, 2014 – Kiadis Pharma B.V. (“Kiadis Pharma”), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product… Continue reading Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™

Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet medical need, is delighted to have won the Scrip ‘Biotech Company of the Year’ Award for 2014, announced last week in London, UK. The prestigious Scrip Awards… Continue reading Prosensa Wins Scrip ‘Biotech Company of the Year’ 2014 Award

 Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate, drisapersen, for Duchenne muscular dystrophy (DMD)  Drisapersen is currently under a rolling review as part of a New Drug Application process and has Orphan, Fast Track and Breakthrough Therapy designation by the FDA  Drisapersen, a potential first-to-market and… Continue reading BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

Amsterdam, The Netherlands, October 30, 2014 – Kiadis Pharma B.V. (“Kiadis Pharma” or “the Company”), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR™ has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML).… Continue reading Kiadis Pharma’s lead product ATIR™ granted Orphan Drug Designation by EMA for the treatment of Acute Myeloid Leukemia